Literature DB >> 16085747

Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience.

N Maliwan1, J R Zvetina.   

Abstract

AIMS: To analyse clinical features and treatment outcomes of patients with pulmonary Mycobacterium kansasii infection treated at Hines VA Hospital between 1952 and 1995, and followed up until 2003.
FINDINGS: 302 patients were confirmed to have M kansasii pulmonary infection; diagnosis was not made until death in 2%. The average age was 50 years old; 76% were white; all were men. Productive cough, dyspnoea, and chest pain were common; 16% were asymptomatic. Right sided, apical or subapical, thin walled cavitary infiltrate was the characteristic radiological feature. Heavy smoking, chronic obstructive pulmonary disease, alcoholism, peptic ulcer disease, coronary artery disease, prior tuberculosis, psychosis, prior pneumonia, and immunocompromising conditions were prevalent. Average follow up was 10 years and 2 months. PPD was positive in 58% of 179 tested. Two thirds of the patients required only first line drugs. Fourteen per cent required surgical intervention, none after 1977. Spontaneous resolution occurred in 1%. Aspergillosis developed in 4%. Bronchogenic carcinoma coexisted with M kansasii infection in 6% and followed it in 4%. Extrapulmonary malignancy coexisted with the infection in 4% and followed it in 6%; most involved head and neck. Eleven per cent of 224 deaths were attributed to M kansasii. Outcomes were affected by comorbidity, treatment compliance, rifampicin use, and extent of infection.
CONCLUSIONS: Prognosis of M kansasii pulmonary infection is good if diagnosed and treated early, together with control of underlying conditions. Clinicians should be aware of atypical radiological manifestations of the disease when coexisting with other pulmonary or immunocompromising conditions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085747      PMCID: PMC1743320          DOI: 10.1136/pgmj.2004.026229

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  19 in total

1.  Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society.

Authors: 
Journal:  Thorax       Date:  2000-03       Impact factor: 9.139

2.  Surgical treatment of pulmonary disease due to Mycobacterium kansasii.

Authors:  J R Zvetina; W E Neville; H C Maben; H T Langston; N O Correll
Journal:  Ann Thorac Surg       Date:  1971-06       Impact factor: 4.330

3.  Isolation of nontuberculous mycobacteria in the United States, 1980.

Authors:  R C Good; D E Snider
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

4.  Mycobacterium kansasii empyema.

Authors:  J R Zvetina; N M Difilippo; M M Ali; M Vandrunen
Journal:  Tubercle       Date:  1981-06

5.  Nontuberculous mycobacterial pulmonary disease.

Authors:  H B Spitz; J F Wiot
Journal:  Semin Roentgenol       Date:  1979-07       Impact factor: 0.800

6.  Pulmonary tuberculosis following successful treatment of pulmonary infection with Mycobacterium kansasii.

Authors:  J R Zvetina; N Nathan; H Facen
Journal:  Chest       Date:  1976-12       Impact factor: 9.410

7.  Mycobacteriosis in patients with malignant disease.

Authors:  R Feld; G P Bodey; D Gröschel
Journal:  Arch Intern Med       Date:  1976-01

8.  Pulmonary cavitations in Mycobacterium kansasii: distinctions from M. tuberculosis.

Authors:  J R Zvetina; T C Demos; N Maliwan; M Van Drunen; W Frederick; J Lentino; A M Modh
Journal:  AJR Am J Roentgenol       Date:  1984-07       Impact factor: 3.959

9.  Incidence and clinical implications of isolation of Mycobacterium kansasii: results of a 5-year, population-based study.

Authors:  K C Bloch; L Zwerling; M J Pletcher; J A Hahn; J L Gerberding; S M Ostroff; D J Vugia; A L Reingold
Journal:  Ann Intern Med       Date:  1998-11-01       Impact factor: 25.391

10.  Pulmonary mycetoma following Mycobacterium kansasii infection. Report of seven cases.

Authors:  N Maliwan; J R Zvetina
Journal:  Arch Intern Med       Date:  1985-12
View more
  14 in total

1.  A case report of a male patient receiving treatment for anorexia nervosa and comorbid obsessive compulsive disorder who was later diagnosed with nontuberculosis Mycobacterium.

Authors:  Brad A MacNeil; Chloe C Hudson; Pallavi Nadkarni; Kathleen Dempsey
Journal:  Eat Weight Disord       Date:  2020-07-24       Impact factor: 4.652

Review 2.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

3.  Mediastinal and Disseminated Mycobacterium kansasii Disease in GATA2 Deficiency.

Authors:  Jana P Lovell; Christa S Zerbe; Kenneth N Olivier; Reginald J Claypool; Cathleen Frein; Victoria L Anderson; Alexandra F Freeman; Steven M Holland
Journal:  Ann Am Thorac Soc       Date:  2016-12

4.  Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii.

Authors:  Moti Chapagain; Tawanda Gumbo; Scott K Heysell; Shashikant Srivastava
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

5.  Mycobacterium kansasii pulmonary infection: CT findings in 29 cases.

Authors:  Masashi Takahashi; Hiroaki Tsukamoto; Tetsuji Kawamura; Yoshirou Mochizuki; Masatsugu Ouchi; Shuhei Inoue; Norihisa Nitta; Kiyoshi Murata
Journal:  Jpn J Radiol       Date:  2012-02-24       Impact factor: 2.374

6.  The Challenge of Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Shannon Novosad; Emily Henkle; Kevin L Winthrop
Journal:  Curr Pulmonol Rep       Date:  2015-07-12

7.  Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

Authors:  Nassr Nassr; Andreas Huennemeyer; Rolf Herzog; Oliver von Richter; Robert Hermann; Manuela Koch; Kevin Duffy; Karl Zech; Gezim Lahu
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

8.  Complement C4 deficiency--a plausible risk factor for non-tuberculous mycobacteria (NTM) infection in apparently immunocompetent patients.

Authors:  Hannele Kotilainen; Marja-Liisa Lokki; Riitta Paakkanen; Mikko Seppänen; Pentti Tukiainen; Seppo Meri; Tuija Poussa; Jussi Eskola; Ville Valtonen; Asko Järvinen
Journal:  PLoS One       Date:  2014-03-17       Impact factor: 3.240

9.  A Case of Mycobacterium kansasii Pulmonary Disease Presenting as Endobronchial Lesions in HIV-Infected Patient.

Authors:  Moon Sung Kim; Ji Won Han; Su Sin Jin; Jong Min Lee; Jick Hwan Hah; Youn Jeong Kim; Seung Joon Kim; Moon Won Kang; Ji Young Kang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-10-29

Review 10.  Gender differences in bronchiectasis: a real issue?

Authors:  Celine Vidaillac; Valerie F L Yong; Tavleen K Jaggi; Min-Min Soh; Sanjay H Chotirmall
Journal:  Breathe (Sheff)       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.